Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination

This cohort study investigates the immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis who had a weak immune response to COVID-19 vaccination.

Detalles Bibliográficos
Autores principales: König, Marton, Torgauten, Hilde Marie, Tran, The Trung, Holmøy, Trygve, Vaage, John Torgils, Lund-Johansen, Fridtjof, Nygaard, Gro Owren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787678/
https://www.ncbi.nlm.nih.gov/pubmed/35072702
http://dx.doi.org/10.1001/jamaneurol.2021.5109
_version_ 1784639409417617408
author König, Marton
Torgauten, Hilde Marie
Tran, The Trung
Holmøy, Trygve
Vaage, John Torgils
Lund-Johansen, Fridtjof
Nygaard, Gro Owren
author_facet König, Marton
Torgauten, Hilde Marie
Tran, The Trung
Holmøy, Trygve
Vaage, John Torgils
Lund-Johansen, Fridtjof
Nygaard, Gro Owren
author_sort König, Marton
collection PubMed
description This cohort study investigates the immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis who had a weak immune response to COVID-19 vaccination.
format Online
Article
Text
id pubmed-8787678
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-87876782022-02-07 Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination König, Marton Torgauten, Hilde Marie Tran, The Trung Holmøy, Trygve Vaage, John Torgils Lund-Johansen, Fridtjof Nygaard, Gro Owren JAMA Neurol Research Letter This cohort study investigates the immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis who had a weak immune response to COVID-19 vaccination. American Medical Association 2022-01-24 2022-03 /pmc/articles/PMC8787678/ /pubmed/35072702 http://dx.doi.org/10.1001/jamaneurol.2021.5109 Text en Copyright 2022 König M et al. JAMA Neurology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Research Letter
König, Marton
Torgauten, Hilde Marie
Tran, The Trung
Holmøy, Trygve
Vaage, John Torgils
Lund-Johansen, Fridtjof
Nygaard, Gro Owren
Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination
title Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination
title_full Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination
title_fullStr Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination
title_full_unstemmed Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination
title_short Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination
title_sort immunogenicity and safety of a third sars-cov-2 vaccine dose in patients with multiple sclerosis and weak immune response after covid-19 vaccination
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787678/
https://www.ncbi.nlm.nih.gov/pubmed/35072702
http://dx.doi.org/10.1001/jamaneurol.2021.5109
work_keys_str_mv AT konigmarton immunogenicityandsafetyofathirdsarscov2vaccinedoseinpatientswithmultiplesclerosisandweakimmuneresponseaftercovid19vaccination
AT torgautenhildemarie immunogenicityandsafetyofathirdsarscov2vaccinedoseinpatientswithmultiplesclerosisandweakimmuneresponseaftercovid19vaccination
AT tranthetrung immunogenicityandsafetyofathirdsarscov2vaccinedoseinpatientswithmultiplesclerosisandweakimmuneresponseaftercovid19vaccination
AT holmøytrygve immunogenicityandsafetyofathirdsarscov2vaccinedoseinpatientswithmultiplesclerosisandweakimmuneresponseaftercovid19vaccination
AT vaagejohntorgils immunogenicityandsafetyofathirdsarscov2vaccinedoseinpatientswithmultiplesclerosisandweakimmuneresponseaftercovid19vaccination
AT lundjohansenfridtjof immunogenicityandsafetyofathirdsarscov2vaccinedoseinpatientswithmultiplesclerosisandweakimmuneresponseaftercovid19vaccination
AT nygaardgroowren immunogenicityandsafetyofathirdsarscov2vaccinedoseinpatientswithmultiplesclerosisandweakimmuneresponseaftercovid19vaccination

Ejemplares similares